Intuitive Surgical, Inc. (NASDAQ:ISRG) Stock Position Reduced by Westwind Capital

Westwind Capital reduced its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 54,057 shares of the medical equipment provider’s stock after selling 277 shares during the period. Intuitive Surgical makes up approximately 6.1% of Westwind Capital’s portfolio, making the stock its 5th biggest position. Westwind Capital’s holdings in Intuitive Surgical were worth $28,216,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the stock. Massachusetts Financial Services Co. MA acquired a new stake in Intuitive Surgical in the third quarter valued at $558,807,000. International Assets Investment Management LLC boosted its holdings in Intuitive Surgical by 49,383.6% in the third quarter. International Assets Investment Management LLC now owns 1,090,619 shares of the medical equipment provider’s stock valued at $535,788,000 after purchasing an additional 1,088,415 shares in the last quarter. FMR LLC increased its stake in Intuitive Surgical by 8.3% in the third quarter. FMR LLC now owns 10,971,085 shares of the medical equipment provider’s stock valued at $5,389,765,000 after purchasing an additional 838,793 shares during the last quarter. Wilmington Savings Fund Society FSB raised its holdings in Intuitive Surgical by 15,322.2% during the third quarter. Wilmington Savings Fund Society FSB now owns 555,661 shares of the medical equipment provider’s stock worth $272,980,000 after purchasing an additional 552,058 shares in the last quarter. Finally, Strategic Financial Concepts LLC boosted its holdings in shares of Intuitive Surgical by 40,221.4% in the 2nd quarter. Strategic Financial Concepts LLC now owns 266,121 shares of the medical equipment provider’s stock valued at $1,184,000 after buying an additional 265,461 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Analyst Upgrades and Downgrades

ISRG has been the subject of a number of research reports. Evercore ISI reissued a “cautious” rating on shares of Intuitive Surgical in a research report on Friday, October 18th. Stifel Nicolaus raised their price target on Intuitive Surgical from $525.00 to $610.00 and gave the stock a “buy” rating in a research note on Thursday, December 5th. Piper Sandler reiterated an “overweight” rating and issued a $538.00 price objective (up previously from $495.00) on shares of Intuitive Surgical in a research note on Friday, October 18th. Raymond James increased their price objective on Intuitive Surgical from $500.00 to $540.00 and gave the stock an “outperform” rating in a research report on Monday, October 14th. Finally, Wells Fargo & Company raised their price objective on shares of Intuitive Surgical from $549.00 to $630.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $554.17.

Intuitive Surgical Stock Performance

NASDAQ ISRG traded down $10.55 during mid-day trading on Tuesday, reaching $531.82. 851,931 shares of the stock were exchanged, compared to its average volume of 1,039,483. Intuitive Surgical, Inc. has a 1-year low of $324.12 and a 1-year high of $556.23. The stock has a market capitalization of $189.42 billion, a PE ratio of 85.50, a PEG ratio of 5.31 and a beta of 1.39. The business’s fifty day simple moving average is $533.39 and its 200 day simple moving average is $492.20.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.24 by $0.32. The firm had revenue of $2.04 billion for the quarter, compared to the consensus estimate of $2.01 billion. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. On average, analysts anticipate that Intuitive Surgical, Inc. will post 5.45 EPS for the current year.

Insider Activity

In related news, CFO Jamie Samath sold 108 shares of the company’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $542.06, for a total transaction of $58,542.48. Following the completion of the sale, the chief financial officer now directly owns 8,757 shares of the company’s stock, valued at approximately $4,746,819.42. This represents a 1.22 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Brian Edward Miller sold 2,553 shares of the firm’s stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $515.00, for a total value of $1,314,795.00. Following the completion of the transaction, the executive vice president now directly owns 7,066 shares in the company, valued at $3,638,990. This trade represents a 26.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 48,190 shares of company stock valued at $25,012,927 in the last ninety days. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.